INTERCEPT Platelets: Journal Articles

1. C Osselaer, C Doyen, L Defoin, C Debry, M Goffaux, N Messe, M Van Hooydonk, A Bosly, JS Lin, L Lin, L Corash. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion. 2009 Jul;49(7):1412-22. [Epub ahead of print]
   > View abstract
   
   
2. SJ Wagner, A Skripchenko, A Myrup, H Awatefe, D Thompson-Montgomery, G Moroff,
   P Carmichael, L Lin. Evaluation of in Vitro Storage Properties of Pre-Storage Pooled Whole Blood-Derived Platelets Suspended in 100 Percent Plasma and Treated with Amotosalen and Long-Wavelength Ultraviolet Light. Transfusion 2009 Apr;49(4):704-10.
   > View abstract
   
   
3. P Rasonglès, MF Angelini-Tibert, P Simon, C Currie, H Isola, D Kientz, M Slaedts, M Jacquet, D Sundin, L Lin, L Corash, JP Cazenave. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion. Transfusion. 2009 Feb 27. [Epub ahead of print]
   > View abstract
   
   
4. V Ciaravino, J Hanover, L Lin, T Sullivan, L Corash. Assessment of Safety in Neonates for Transfusion of Platelets and Plasma Prepared with Amotosalen Photochemical Pathogen Inactivation Treatment by a One-month Intravenous Toxicity Study in Neonatal Rats. Transfusion 2009 Jan 19. [Epub ahead of print]
   > View abstract
   
   
5. P Grellier, J Benach, M Labaied, S Charneau, H Gil, G Monsalve, R Alfonso, L Sawyer, L Lin, M Steiert, K Dupuis. Photochemical Inactivation with Amotosalen and Long-Wavelength Ultraviolet Light of Plasmodium and Babesia in Platelet and Plasma Components. Transfusion 2008 Aug;48(8):1676-84.
   > View abstract
   
   
6. Tice RR, Gatehouse D, Kirkland D, Speit G. The pathogen reduction treatment of platelets with S-59 HCI (Amotosalen) plus ultraviolet A light: Genotoxicity profile and hazard assessment. Mutation Research 2007; 630:50-68.
   > View abstract
   
   
7. Brecher ME, Hay S, Corash L, et al. Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment. Transfusion 2007;47(10):1896-1901.
   > View abstract
   
   
8. Nussbaumer W, Allersdorfer D, Grabmer C, et al. Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacterial culture and pathogen inactivation methods. Transfusion 2007, 47(7):1125-1133.
   > View abstract
   
   
9. Sawyer L, Hanson C, Castro G, e al. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007; 47(6):1062-1070.
   > View abstract
   
   
10. Lozano M, Galan A, Mazzara R, et al. Leukoreduced buffy coat derived platelet concentrates photochemically treated with amotosalen HCI and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007; 47(4): 666-671.
    > View abstract
    
    
11. Castro E, Gironés N, Bueno JL, et al. The efficacy of photochemical treatment with amotosalen HCl and UVA (INTERCEPTTM) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007, 47(3):434-441.
    > View abstract
    
    
12. Isola H, Kientz D, Aleil B, et al. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. Vox Sang 2006;90(2):128-30.
    > View abstract
    
    
13. Murphy S, Snyder E, Cable R, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006;46(1):24-33.
    > View abstract
    
    
14. Pineda A, McCullough J, Benjamin RJ, et al. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion 2006;46(4):562-71.
    > View abstract
    
    
15. Roback JD, Conlan M, Drew WL, et al. The role of photochemical treatment with amotosalen and UVA light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006;20(1):45-56.
    > View abstract
    
    
16. Simonsen AC, Johansson PI, Conlan MG, et al. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006;46(3):424-33.
    > View abstract
    
    
17. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006;46(5):731-40.
    > View abstract
    
    
18. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45(12):1864-75.
    > View abstract
    
    
19. Schlenke P, Kirchner H, Corash L. Concerning Caspari et al: Pathogen Inactivation of Cellular Blood Products-- More Security for the Patient or Less? Transfusion Medicine and Hemotherapy 2005;32(1):45-8.
    
    
20. Postma MJ, van Hulst M, De Wolf JT, et al. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005;15(5):379-87.
    > View abstract
    
    
21. Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005;15(4):269-76.
    > View abstract
    
    
22. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45(4):580-90.
    > View abstract
    
    
23. Lin L, Conlan MG, Tessman J, et al. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 2005;45(10):1610-20.
    > View abstract
    
    
24. Jauvin V, Alfonso RD, Guillemain B, et al. In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen. Transfusion 2005;45(7):1151-9.
    > View abstract
    
    
25. Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45(9):1443-52.
    > View abstract
    
    
26. Eastman RT, Barrett LK, Dupuis K, et al. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005;45(9):1459-63.
    > View abstract
    
    
27. Bruchmuller I, Losel R, Bugert P, et al. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets 2005;16(8):441-5.
    > View abstract
    
    
28. Bruchmuller I, Janetzko K, Bugert P, et al. Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates. Transfusion 2005;45(9):1464-72.
    
    
29. Blajchman MA, Beckers EA, Dickmeiss E, et al. Bacterial Detection of Platelets: Current Problems and Possible Resolutions. Transfus Med Rev 2005;19(4):259-72.
    
    
30. Benjamin RJ. Bacterial detection in platelet components and the rationale for pathogen inactivation: A blood center perspective. J Clin Apheresis 2005;20(2):117-22.
    
    
31. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19(2):110-26.
    
    
32. Wollowitz S. Targeting DNA and RNA in Pathogens: Mode of Action of Amotosalen HCl. Transfusion Medicine and Hemotherapy 2004;31(Suppl. 1):11-6.
    
    
33. van Rhenen DJ, Gulliksson H, Cazenave JP, et al. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution. Transfus Med 2004;14(4):289-95.
    
    
34. Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 2004;80(4):317-24.
    
    
35. Snyder E, Raife T, Lin L, et al. Recovery and life span of ¹¹¹indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44(12):1732-40.
    
    
36. Schlenke P. Protection against Transfusion-Associated Graft-versus-Host Disease in Blood Transfusion: Is Gamma-Irradiation the Only Answer? Transfusion Medicine and Hemotherapy 2004;31(Suppl. 1):24-31.
    
    
37. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44(3):320-9.
    
    
38. Picker SM, Speer R, Gathof BS. Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization. Transfus Med 2004;14(3):217-23.
    
    
39. Moog R, Frohlich A, Mayaudon V, Lin L. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. J Clin Apheresis 2004;19(4):185-91.
    
    
40. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104(5):1534-41.
    
    
41. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004;125(2):107-16.
    
    
42. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44(10):1496-504.
    
    
43. Jordan CT, Saakadze N, Newman JL, et al. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion 2004;44(8):1159-65.
    
    
44. Janetzko K, Lin L, Eichler H, et al. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004;86(4):239-45.
    
    
45. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004;33(1):1-7.
    
    
46. Van Voorhis WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003;47(2):475-9.
    
    
47. van Rhenen D, Gulliksson H, Cazenave J-P, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101(6):2426-33.
    
    
48. Corash L. Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr Hematol Rep 2003;2(6):495-502.
    
    
49. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 2003;25(9):2464-86.
    
    
50. Janetzko K, Klinger M, Mayaudon V, et al. Storage Characteristics of Split Double-Dose Platelet Concentrates Derived from Apheresis and Treated with Amotosalen Hydrochloride and UVA Light for Pathogen Inactivation. Transfusion Medicine and Hemotherapy 2002;29(4):193-8.
    
    
51. Janetzko K, Corash L, Lin L, et al. In vitro function of double-dose platelets treated with the pathogen inactivation Helinx™ technology. In: Holick MF, ed. Biologic Effects of Light 2001. Boston, MA: Kluwer Academic Publishers, 2002:313-23.
    
    
52. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001;38(4 Suppl 11):4-11.
    
    
53. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx technology. Semin Hematol.. 2001; 38(4 Suppl 11):27-33.
    
    
54. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol. 2001;20(10):533-50.
    
    
55. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective. Semin Hematol. 2001;38(4 Suppl 11):12-9.
    
    
56. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000;79(4):206-14.
    
    
57. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78(4):209-16.
    
    
58. Hei DJ, Grass J, Lin L, et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999;39(3):239-48.
    
    
59. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999;93(9):3140-7.
    
    
60. Lin L, Alfonso R, Behrman B, et al. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Transfusion Medicine and Hemotherapy 1998;25(1):39-48.
    
    
61. Lin L. Psoralen photochemical treatment of platelets. Science and Medicine 1998;5(1):54-63.
    
    
62. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91(6):2180-8.
    
    
63. Lin L, Cook DN, Wiesehahn, GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37(4):423-35.

[back to top]